Global Capecitabine Market – Industry Trends and Forecast to 2029

Global Capecitabine Market, By Indication (Colorectal Cancer, Breast Cancer, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Capecitabine Market Analysis and Size

The global capecitabine market is expected to witness significant growth during the forecast period. The growth of capecitabine market enhanced by the rise in cases of cancer worldwide and patent expiry of capecitabine. The growing global burden of patients diagnosed with cancer and tumors is likely to drive the market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global capecitabine market in the forecast period 2022-2029. The expected CAGR of global capecitabine market is tend to be around 6% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Capecitabine is commercialized under the trade name of Xeloda is a chemotherapeutic agent that widely used in the treatment of metastatic breast and colorectal cancers. Capecitabine is act as thymidylate synthase inhibitor and hence preventing the progression of abnormal cells. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Capecitabine Market Scope and Segmentation

Global Capecitabine Market Dynamics

Drivers

• Increase in Cancer Cases

The rise in cancer cases globally boosts the global capecitabine market in the forecast period As per the WHO report, cancer is the major cause of mortality worldwide and estimated that approximately 9.6 million deaths in 2018. Moreover, it is projected that 627,000 women died from breast cancer, around 15% of all cancer deaths among women across the globe. This boost the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Patent Expiration Encourages New Launches

The patent expiration of old companies can create better opportunities for the new market players. The adoption of combination therapies is a significant factor that contributes to the growth of the capecitabine market. Further, R&D fundings are an add-on to the market.

• Growing Awareness Programs

There has been growing awareness programs on the cancer disease and drugs that leads to the growth of the market. In addition to this, increasing awareness programs by governments and private organizations such as Cancer Suraksha Scheme, Cancer Care, Cancer Research UK, are anticipated to propel the global capecitabine market growth over the course of the period

• Rising Healthcare Awareness

Awareness among patients as well as healthcare providers about the incidence of types of cancer is on the rise. Patients and doctors are now more actively participating in learning about the therapies that are available for the treatment of these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global capecitabine market over a forecast period.

• Increasing Cost Of Treatments

The huge expenditure required for the treatment methods surely hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.

This global capecitabine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global capecitabine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Capecitabine Market Scope

The global capecitabine market is segmented on the basis of indication, drug type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Colorectal Cancer
• Breast Cancer
• Others

Drug Type

• Branded
• Generic

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Capecitabine Market Regional Analysis/Insights

The global capecitabine market is analysed and market size insights and trends are provided by indication, drug type, distribution channel and end-user as referenced above.

The major countries covered in the global capecitabine market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to have the highest market growth due to the prevalence of cancer and vulnerable geriatric population.

North America dominates the market due to the presence of key generic pharmaceuticals companies in this region and rise in government initiatives and special communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Capecitabine Market Share Analysis

The global capecitabine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global capecitabine market.

Key players operating in the global capecitabine market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Alkem Labs Ltd (India)